Coherus Oncology (CHRS) Cash from Operations Growth (5y) (2018 - 2026)
Coherus Oncology (CHRS) Cash from Operations Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Coherus Oncology | 194.37 Mn | 27.32 Mn | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -113.49% |
| Dec 31, 2025 | -21.01% |
| Sep 30, 2025 | -24.39% |
| Jun 30, 2025 | -22.64% |
| Mar 31, 2025 | -31.39% |
| Dec 31, 2024 | 10.07% |
| Sep 30, 2024 | -25.62% |
| Jun 30, 2024 | 36.35% |
| Mar 31, 2024 | 3.87% |
| Dec 31, 2023 | 22.86% |
| Sep 30, 2023 | -4.88% |
| Jun 30, 2023 | -1.84% |
| Mar 31, 2023 | -15.40% |
| Dec 31, 2022 | -27.28% |
| Sep 30, 2022 | 2.23% |
| Jun 30, 2022 | 2.08% |
| Mar 31, 2022 | 5.91% |
| Dec 31, 2021 | 9.65% |
| Sep 30, 2021 | 17.31% |
| Jun 30, 2021 | 63.08% |